What’s inside
View ResearchExplore innovative anti-EGFRvIII CAR T cell therapy enhanced with a SIRPγ-derived CD47 blocker for glioblastoma. This approach overcomes the immunosuppressive tumor microenvironment and improves efficacy by modulating glioma-associated microglia and macrophages. In vitro and in vivo studies show significant tumor elimination and long-term survival benefits, surpassing conventional CAR T cell therapies.
Enhancing CAR T Cell Therapy for Glioblastoma
Exploration of combining anti-EGFRvIII CAR T cells with SIRPγ-derived CD47 blocker for effective glioblastoma treatment.
Overcoming Glioblastoma's Tumor Microenvironment
Strategies to enhance CAR T cell therapy by disrupting CD47-SIRPα axis in glioblastoma's tumor microenvironment.
Combining CAR T Cells with Paracrine Modulation
Study on local CAR T cell therapy combined with paracrine modulation for eliminating glioblastoma.
Anti-EGFRvIII-SGRP CAR T Cells Efficacy
Anti-EGFRvIII-SGRP CAR T cells show dose-dependent elimination of GBM in vitro and in vivo.
Enhanced Survival with Anti-EGFRvIII-SGRP CAR T Cells
Significant long-term survival in glioblastoma models with anti-EGFRvIII-SGRP CAR T cell therapy.
Anti-EGFRvIII-SGRP CAR T Cells vs. Anti-CD47 Antibodies
Superior efficacy of anti-EGFRvIII-SGRP CAR T cells over anti-CD47 antibodies in glioblastoma treatment.
.svg)
.jpg)
.webp)
